STOCK TITAN

Protagenic raises about $1.5M in private placement

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

PTIX completed the initial closing of a private placement covering 2,459,014 common shares and Series A and Series B warrants, each to purchase up to 2,459,014 shares, at $0.61 per share with accompanying warrants. The company received approximately $1.5 million in gross proceeds before fees and expenses. The agreement permits additional closings through the earlier of December 31, 2026, or sale of the maximum offering amount: $3 million, which the company may increase to up to $5 million. The company said total potential gross proceeds could reach $5 million, including up to $3.5 million if both warrant series are exercised in full.

The warrants are immediately exercisable for cash at $0.67 per share for Series A and $0.73 for Series B. PTIX plans to use net proceeds for product development, clinical programs and operating expenses, including PT00114 development and its planned Phase 1/2a trial for generalized anxiety disorder. First-patient dosing is targeted for the second quarter of 2027, subject to FDA review of the IND; topline safety data are expected in the second half of 2027 and exploratory efficacy data in the first half of 2028. PTIX agreed to file a resale registration statement within 45 days and use commercially reasonable efforts to have it declared effective within 90 days, or 150 days in the event of a full SEC review.

Filing Explained

Placement-agent fees reduce retained proceeds, and agent warrants add potential share issuance beyond the investor securities.

At the completed initial closing, no pre-funded warrants were issued. The agreement also provides for placement-agent compensation: a cash fee of 7% of gross proceeds at each closing, a 1% expense allowance, and warrants equal to 7% of investor common warrants issued. Those agent warrants add potential share issuance, while the cash fee and allowance reduce proceeds retained by the company.

For later closings, a purchaser whose share purchase would put its beneficial ownership above 4.99% (or its elected 9.99% limit) may choose pre-funded warrants instead of shares. If warrants are exercised for shares, the increased share count reduces existing holders’ percentage ownership absent offsetting changes.

The company also agreed, subject to exceptions, not to issue common shares or equivalents until 45 days after the agreement’s Effective Date, and not to enter into a variable-rate transaction until the first anniversary of that Effective Date.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Initial gross proceeds Approximately $1.5 million Received at the November 17, 2026 initial closing, before placement agent fees and other offering expenses
Common shares sold 2,459,014 shares Private placement initial closing
Purchase price $0.61 per share For common stock and accompanying common warrants
Series A warrants Up to 2,459,014 shares Exercise price of $0.67 per share
Series B warrants Up to 2,459,014 shares Exercise price of $0.73 per share
Potential gross proceeds Up to $5 million Company announcement; includes up to $3.5 million if both warrant series are exercised in full
First-patient dosing target Second quarter of 2027 PT00114 Phase 1/2a trial, subject to FDA review of the IND
volume weighted average price financial
"90% of the volume weighted average price"
The volume weighted average price (VWAP) is a way to measure the average price of a security, such as a stock, over a specific period, taking into account how many units were traded at each price. It’s similar to calculating the average cost of items bought when some are more frequently purchased than others. Investors use VWAP to assess whether a security is being bought or sold at a fair price during trading.
Pre-Funded Warrants financial
"purchase pre-funded warrants to purchase shares of Common Stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
IND regulatory
"subject to FDA review of the IND"
chemistry, manufacturing and controls (CMC) technical
"completing the associated chemistry, manufacturing and controls (CMC) work"
Chemistry, manufacturing and controls (CMC) is the set of scientific and operational steps that show how a drug or biologic is made, what goes into it, and how its quality is consistently checked—think of it as the recipe, the factory process, and the quality checklist for a medicine. Investors care because strong CMC reduces risks around regulatory approval, production delays, batch failures and unexpected costs, directly affecting a product’s ability to reach market and generate revenue.
ascending-dose cohorts medical
"ascending-dose cohorts that evaluate safety, tolerability and pharmacokinetics"
Hamilton Anxiety Rating Scale (HAM-A) medical
"change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did PTIX raise in its private placement?

PTIX received approximately $1.5 million in gross proceeds at the initial closing, before placement agent fees and other offering expenses. The company said total potential gross proceeds could reach $5 million, including up to $3.5 million if the two warrant series are exercised in full.

What are the PTIX private placement warrant terms?

The placement included Series A and Series B warrants, each for up to 2,459,014 shares. They are immediately exercisable for cash at $0.67 and $0.73 per share, respectively. No pre-funded warrants were issued at the initial closing.

When does PTIX expect to dose the first patient in the PT00114 trial?

PTIX targets first-patient dosing in the second quarter of 2027, subject to FDA review of the IND. The company expects topline safety data in the second half of 2027 and exploratory efficacy data in the first half of 2028.

What are PTIX's resale registration deadlines for the private placement shares?

PTIX agreed to file one or more resale registration statements within 45 days and use commercially reasonable efforts to have a statement declared effective within 90 days, or 150 days in the event of a full SEC review. The agreement provides for liquidated damages if the deadlines are missed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001022899 0001022899 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

 

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported):   November 17, 2026

 

PROTAGENIC THERAPEUTICS, INC.  

 

(Exact name of Company as specified in its charter)

 

Delaware   001-12555   06-1390025

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

149 Fifth Avenue, Suite 500, New York, NY   10010
(Address of principal executive offices)   (Zip Code)

 

212-994-8200

 

(Company’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Ticker symbol(s)   Name of each exchange on which registered
         

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On November 10, 2026, Protagenic Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”). Under the Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in a private placement offering (the “Private Placement”), the following securities at the Initial Closing (as defined below): (i) 2,459,014 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”); (ii) Series A common stock purchase warrants to purchase up to 2,459,014 shares of Common Stock (the “Series A Warrants”); and (iii) Series B common stock purchase warrants to purchase up to 2,459,014 shares of Common Stock (the “Series B Warrants” and, together with the Series A Warrants, the “Common Warrants”).

 

The purchase price was $0.61 per share of Common Stock and accompanying Common Warrants. This price equals 90% of the volume weighted average price of the Common Stock for the 30 consecutive trading days ending on the trading day immediately preceding the date of the Purchase Agreement. The Purchasers’ subscription amounts were deposited with Odyssey Transfer and Trust Company, as escrow agent, under an escrow agreement dated as of September 25, 2026. Under the Purchase Agreement, the purchase price per Pre-Funded Warrant and accompanying Common Warrants is equal to the per-share purchase price minus $0.0001.

 

The initial closing of the Private Placement occurred on November 17, 2026 (the “Initial Closing”). At the Initial Closing, the Company received gross proceeds of approximately $1.5 million, before deducting placement agent fees and other offering expenses.

 

Under the Purchase Agreement, the Company may sell additional securities on the same terms at one or more subsequent closings until the earlier of (i) December 31, 2026 and (ii) the date on which the maximum offering amount has been sold. The maximum offering amount is $3,000,000, which the Company may increase in its discretion to up to $5,000,000.

 

Pre-Funded Warrants. Under the Purchase Agreement, any Purchaser whose purchase of shares of Common Stock in the Private Placement would otherwise result in that Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the Purchaser’s election, 9.99%) of the Company’s outstanding Common Stock immediately following the applicable closing may elect to purchase pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) in lieu of shares of Common Stock. The Pre-Funded Warrants, if any, have an exercise price of $0.0001 per share, are immediately exercisable and remain exercisable until exercised in full. No Pre-Funded Warrants were issued at the Initial Closing.

 

Common Warrants. The Common Warrants are exercisable for cash only, beginning immediately upon issuance. The Series A Warrants have an exercise price of $0.67 per share, equal to 110% of the per-share purchase price. The Series B Warrants have an exercise price of $0.73 per share, equal to 120% of the per-share purchase price.

 

Each Common Warrant expires at 5:00 p.m. (New York City time) on the earliest of:

 

  (i) the fifth anniversary of its issuance date;
     
  (ii) the 30th day following the last day of any period of 10 consecutive trading days during which the volume weighted average price of the Common Stock equals or exceeds 200% of the per-share purchase price; and
     
  (iii) the 30th day following the Company’s public disclosure of the dosing of the tenth patient in its planned Phase 1/2a clinical trial of PT00114 in Generalized Anxiety Disorder.

 

Beneficial ownership limitation. A holder of a Common Warrant or Pre-Funded Warrant may not exercise any portion of the warrant if the holder, together with its affiliates, would then beneficially own more than 4.99% (or, at the holder’s election, 9.99%) of the shares of Common Stock outstanding immediately after giving effect to the exercise.

 

 

 

 

Covenants. The Purchase Agreement contains customary representations, warranties and covenants of the Company and the Purchasers, and customary indemnification obligations. Under the Purchase Agreement, the Company has agreed not to issue or agree to issue shares of Common Stock or Common Stock equivalents, subject to certain exceptions, from the date of the Purchase Agreement until 45 days after the Effective Date (as defined in the Purchase Agreement). The Company has also agreed not to enter into any variable rate transaction until the first anniversary of the Effective Date.

 

Use of proceeds. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including product development, clinical programs and operating expenses.

 

Placement agent. Brookline Capital Markets, a division of Arcadia Securities, LLC (the “Placement Agent”), acted as placement agent for the Private Placement under a placement agency agreement dated as of June 19, 2026 (the “Placement Agency Agreement”). Under the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds of the Private Placement, payable at each closing from the escrow account, and a non-accountable expense allowance equal to 1.0% of the aggregate gross proceeds of the Private Placement, and to reimburse the Placement Agent for certain of its reasonable and documented out-of-pocket expenses, up to $75,000 without the Company’s prior written approval. The Company also agreed to issue to the Placement Agent, a number of Placement Agent Warrants equivalent to 7.0% of the total number of Common Warrants issued to investors in the Private Placement (the “Placement Agent Warrants”). The Company also agreed to indemnify the Placement Agent against certain liabilities. Pursuant to the Placement Agency Agreement, the Company’s directors, executive officers, employees and certain shareholders entered into “lock-up” agreements pursuant to which they have agreed, subject to certain exceptions, not to sell or transfer any securities of the Company that they hold for a period of ninety (90) days from the final closing of the Private Placement.

 

Registration rights. In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchasers (the “Registration Rights Agreement”). Under the Registration Rights Agreement, the Company agreed to file one or more registration statements with the Securities and Exchange Commission (the “SEC”) to register the resale of the shares of Common Stock sold in the Private Placement and the shares issuable upon exercise of the Pre-Funded Warrants and Common Warrants. The Company agreed to file within 45 days and to use commercially reasonable efforts to have the registration statement declared effective within 90 days (or 150 days in the event of a “full review” by the SEC). The Company is subject to liquidated damages if it fails to meet these deadlines.

 

Exempt offering. None of the securities sold in the Private Placement, the Placement Agent Warrants, or the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the Common Warrants and the Placement Agent Warrants, have been registered under the Securities Act of 1933, as amended (the “Securities Act”). These securities were offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.

 

The Purchase Agreement is filed as an exhibit to this Current Report on Form 8-K to provide investors and stockholders with information regarding its terms. It is not intended to provide any other factual information about the Company or the Purchasers. The representations, warranties and covenants in the Purchase Agreement were made solely for the purposes of that agreement and as of specific dates, and solely for the benefit of the parties to it. They may be subject to limitations agreed upon by the contracting parties, may have been made to allocate contractual risk among the parties rather than to establish matters as facts, and may be subject to standards of materiality that differ from those applicable to investors. Investors are not third-party beneficiaries under the Purchase Agreement and should not rely on the representations, warranties and covenants as characterizations of the actual state of facts or condition of the Company.

 

The foregoing descriptions of the Purchase Agreement, the Registration Rights Agreement, the Pre-Funded Warrants,, the Series A Warrants, the Series B Warrants and the Placement Agent Warrants are not complete. Each is qualified in its entirety by reference to the full text of the applicable document (or form), filed as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5 and 10.6, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

 

 

 

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. Based in part on the representations of the Purchasers in the Purchase Agreement, the offer and sale of the securities in the Private Placement is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and under corresponding provisions of state securities or “blue sky” laws. Each Purchaser represented that it is an accredited investor and is acquiring the securities for its own account and not with a view to distribution. The securities were offered without any general solicitation by the Company or its representatives.

 

Item 7.01 Regulation FD Disclosure.

 

On November 11, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference into this Item 7.01. The information contained in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, except to the extent expressly stated in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are being filed herewith:

 

Exhibit No.   Description
10.1   Form of Securities Purchase Agreement
10.2   Form of Registration Rights Agreement
10.3   Form of Pre-funded Warrant
10.4   Form of Series A Warrant
10.5   Form of Series B Warrant
10.6   Form of Placement Agent Warrant
99.1   Press Release dated November 11, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTAGENIC THERAPEUTICS, INC.
     
Date: November 17, 2026 By: /s/ Bill Nichols
  Name: Bill Nichols
  Title: President

 

 

 

 

Exhibit 99.1

 

 

Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into its First U.S. Clinical Trial in Generalized Anxiety Disorder

 

●$1.5 million upfront financing, along with up to $3.5 million upon exercise of milestone-linked warrants, is expected to fund IND-enabling activities and initiation of the Phase 1/2a trial of PT00114

 

●Phase 1/2a design is intended to generate both safety data and an early efficacy signal in patients with GAD within a single study

 

●IND submission targeted for late Q1 2027, incorporating FDA’s pre-IND requests; first patient dosing targeted for Q2 2027, consistent with the Company’s previously announced first-half 2027 timeline

 

●Topline safety data expected in 2H 2027; exploratory efficacy data expected in 1H 2028

 

NEW YORK, NY, November 11, 2026 / ACCESS Newswire / — Protagenic Therapeutics, Inc. (OTCQB: PTIX) (“Protagenic” or the “Company”), a clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for stress-related neuropsychiatric disorders, today announced a private placement with new and existing investors that provides $1.5 million in upfront gross proceeds. Up to $3.5 million in additional gross proceeds may be received if two series of milestone-linked warrants are exercised in full, for total potential gross proceeds of up to $5 million, before deducting placement agent fees and offering expenses.

 

The Company intends to use the proceeds to complete IND-enabling activities for PT00114, its lead asset; to initiate its planned Phase 1/2a clinical trial in Generalized Anxiety Disorder (GAD); and for working capital and general corporate purposes. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as sole placement agent for the financing.

 

PT00114 Development Update

 

In August 2026, Protagenic received written responses from the U.S. Food and Drug Administration (FDA) to its Type B pre-IND meeting request for PT00114 in GAD. FDA identified no deficiencies that would preclude submission of an IND. Since then, the Company has been incorporating FDA’s requests into its submission and completing the associated chemistry, manufacturing and controls (CMC) work, including refined CMC specifications and expanded dose cohorts. The Company has also finalized its Phase 1/2a study design.

 

The Phase 1/2a trial will include ascending-dose cohorts that evaluate safety, tolerability and pharmacokinetics, followed by a cohort of patients with GAD. The patient cohort will further evaluate safety and assess exploratory measures of efficacy, including change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score. This design is intended to provide early clinical evidence of PT00114’s activity in its target population within the Company’s first U.S. study.

 

 

 

 

First patient dosing is targeted for the second quarter of 2027, subject to FDA review of the IND, which is consistent with the first-half 2027 timeline the Company previously announced. The Company expects topline safety data in the second half of 2027 and exploratory efficacy data in the first half of 2028.

 

The U.S. program builds on two completed Phase 1 studies of PT00114 conducted outside the United States: a single ascending dose study in May 2024 and a multiple ascending dose study, for which the Company reported positive topline safety results in December 2025. In the multiple ascending dose study, PT00114 was well tolerated across all dose levels studied, and no serious adverse events were observed.

 

“We are encouraged by FDA’s feedback on our pre-IND package for PT00114 in Generalized Anxiety Disorder, and we are moving quickly to submit our IND and bring this program into the U.S. clinic,” said Bill Nichols Jr., President of Protagenic. “Our plan, informed by FDA’s feedback, is designed to establish the safety of our novel neuropeptide along with an early efficacy signal in patients with Generalized Anxiety Disorder. We expect this financing to take us into the clinic and to the enrollment of our first patients, which we believe will be a value inflection point for the Company. We continue to pursue strategic options and additional capital so that our priority R&D work is well resourced.”

 

About PT00114

 

PT00114 is Protagenic’s lead clinical asset. It is a first-in-class investigational neuropeptide and a synthetic analog of teneurin C-terminal associated peptide (TCAP), a naturally occurring brain peptide thought to help regulate the body’s response to stress. Protagenic is developing PT00114 for stress-related neuropsychiatric disorders, with an initial focus on Generalized Anxiety Disorder and potential future applications in PTSD and treatment-resistant depression. PT00114 has completed single ascending dose and multiple ascending dose Phase 1 studies outside the United States. In the multiple ascending dose study, it was well tolerated with no serious adverse events observed across dose levels. Protagenic plans to begin its first U.S. clinical trial, a Phase 1/2a study in GAD, in the second quarter of 2027.

 

About Protagenic Therapeutics, Inc.

 

Protagenic Therapeutics, Inc. (OTCQB: PTIX) is a clinical-stage biopharmaceutical company dedicated to developing breakthrough peptide-based treatments for stress-related neuropsychiatric disorders. The Company is headquartered in New York, NY. For more information, visit www.protagenic.com.

 

 

 

 

The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Rule 506(b) of Regulation D promulgated thereunder and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. Pursuant to the terms of the registration rights agreement entered into with the investors, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) covering the resale of the shares of common stock and the shares of common stock underlying the pre-funded warrants and common warrants sold in the offering.

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include, but are not limited to, statements regarding: the closing of the financing and the anticipated use of proceeds; the potential exercise of the milestone-linked warrants and the proceeds from any such exercise; the anticipated timing of the Company’s IND submission, FDA review, and first patient dosing; the completion of CMC activities; the design, conduct, and timing of data from the planned Phase 1/2a study of PT00114; the Company’s expectations regarding its liquidity, capital resources, and ability to raise additional financing; and the therapeutic potential of PT00114 in Generalized Anxiety Disorder and other stress-related disorders. These statements are based on current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied. These risks include, among others: the Company’s ability to continue as a going concern; whether milestones are achieved and the warrants are exercised; the availability and terms of additional financing; the risk of delays in CMC or manufacturing activities; the risk that FDA’s pre-IND advice is non-binding and that FDA may request additional information, impose a clinical hold, or otherwise delay the program; the inherent uncertainty of clinical development, including that results from exploratory endpoints or early-stage studies may not be predictive of later results; and other risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended March 31, 2026. Because the Company’s common stock may be considered “penny stock,” the statutory safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995 may not be available to the Company, and the Company therefore also relies on the protections afforded by the “bespeaks caution” doctrine. Protagenic Therapeutics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

 

Investor & Media Contact:

 

Protagenic Therapeutics, Inc. | info@protagenic.com | www.protagenic.com

 

 

 

 

Filing Exhibits & Attachments

11 documents

Keep reading